Selenium in radiation oncology - Experiences and prospects

Trace Elements and Electrolytes

Volumn 28, Issue 3, 2011, Pages 168-177

  Muecke, R ^a   Micke, O ^b   Schomburg, L ^c   Buentzel, J ^d   Kisters, K ^e   Adamietz, I A ^f  

^a Lippe Hospital Lemgo   (Germany)

^b FRANZISKUS HOSPITAL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Südharz Hospital Nordhausen   (Germany)

^e ST ANNA HOSPITAL   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Blood and tissue selenium levels; Experimental and clinical data on radioprotection by selenium; Selenium use in lymphedemas

Indexed keywords

CYSTAMINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE PEROXIDASE; PROTEIN KINASE B; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; SELENITE; SELENIUM; SELENOCYSTAMINE; SELENOPROTEIN P; SODIUM SELENITE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

AGEUSIA; APOPTOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARTILAGE CELL; CELL PROTECTION; CLONOGENIC ASSAY; DIARRHEA; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DYSPHAGIA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ERYSIPELAS; GLIOMA CELL; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HUMAN; LARYNX EDEMA; LUNG CANCER; LYMPHEDEMA; MASTECTOMY; MEDLINE; MINERAL BLOOD LEVEL; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; OSTEOBLAST; PATIENT IDENTIFICATION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RADIOSENSITIVITY; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SECONDARY PREVENTION; SELENIUM DEFICIENCY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SYSTEMATIC REVIEW; TISSUE LEVEL; UTERUS CARCINOMA; WILD TYPE; XEROSTOMIA;

ANIMALIA; RATTUS;

EID: 79959409434     PISSN: 09462104     EISSN: None     Source Type: Journal    
DOI: 10.5414/TEP28168     Document Type: Review

References (85)

1. Micke O, Muecke R, Buentzel J, Kisters K, Schaefer U. Some more steps on the way to clinical elementology. Trace Elem Electrolytes. 2010; 27: 29-34.
2. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox. Signal 2007; 9: 775-806.
3. Rayman MP. The importance of selenium to human health. Lancet. 2000; 356: 233-241. (Pubitemid 30446984)
4. Schomburg L, Schweizer U, Koehrle J. Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic. Cell Mol Life Sci. 2004; 61: 1988-1995. (Pubitemid 39149889)
5. Burk RF, Hill KE, Motley AK. Plasma selenium in specific and non-specific forms. Biofactors. 2001; 14: 107-114. (Pubitemid 32848305)
6. Coombs GF Jr. Selenium in global food systems. Br J Nutr. 2001; 85: 517-547.
7. Hoefig CS, Renko K, Köhrle J, Birringer M, Schomburg L. Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. J Nutr Biochem. 2010; Dec 27 [Epub ahead of print] S1873-S4847.
8. Brooks JD, Metter EJ, Chan DW. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urolog. 2001; 166: 2034-2038. (Pubitemid 33065210)
9. Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol. 2006; 13: 1180-1184. (Pubitemid 44410906)
10. Knekt P, Aromaa A, Mantela J. Serum selenium and subsequent risk of cancer among Finnish men and woman. J Natl Cancer Inst. 1990; 82: 864-868. (Pubitemid 20149447)
11. Paulowicz Z, Zachara BA, Trafikowska U, Maciag A, Marchaluk E, Nowicki A. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes. 1995; 12: 186-190.
12. Torun M, Aldemir H, Yardim S. Serum selenium levels in various cancer types. Trace Elem Electrolytes. 1995; 12: 186-190.
13. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park, HK, Sanders BB, Smith CI, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996; 276: 1957-1963. (Pubitemid 26427723)
14. Shu-You Y, Ya-Jun Z, Wen-Guang Li, Qui-Sheng H, Zhi-Huang Ch, Qi-Nan Zh, Chong H. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in china. Biol Trace Elem Res. 1991; 29: 289-294.
15. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009; 301: 39-51.
16. Kvicala J, Zamrazil V, Nemecek J, Jiranek V. In fluence of long-term supplementation by various quantities of yeast-bound selenium upon selenium- status of South Bohemia seniors. Trace Elem Electrolytes. 2011; 28: 11-17.
17. Buentzel J, Micke O, Kisters K, Bruns F, Glatzel M, Schoenekaes KG, Schaefer U, Muecke R. Selenium substitution during radiotherapy of solid tumours - laboratory data from two observation studies in gynaecologic and head and neck cancer patients. Anticancer Research. 2010; 30: 1783-1786.
18. Buentzel J, Knolle U, Garayev A, Muecke R, Schaefer U, Kisters K, Schoenekaes KG, Hunger R, Bruns F, Glatzel M, Micke O. Trace elements selenium and zinc as tumor markers in patients with advanced head and neck cancer. Trace Elem Electrolytes. 2010; 27: 246-249.
19. Muecke R, Micke O, Schoenekaes KG. Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2000; 17: 119-123. (Pubitemid 30465927)
20. Muecke R, Klotz Th, Giedl J, Buentzel J, Kundt G, Kisters K, Prott FJ, Micke O. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH. Acta Oncologica. 2009; 48: 239-246.
21. Muecke R, Buentzel J, Glatzel M, Bruns F, Kisters K, Prott FJ, Schmidberger H, Micke O. Postoperative serum and whole blood selenium levels in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment. Trace Elem Electrolytes. 2009; 26: 78-82.
22. Meyer HA, Hollenbach B, Stephan C, Endermann T, Morgenthaler NG, Cammann H, Kohrle J, Jung K, Schomburg L. Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2386-2390.
23. Breccia A, Badiello R, Trenta M, Mattii M. On the chemical radioprotection by organic selenium compounds in vivo. Radiat Res. 1969; 38: 483-492.
24. Diamond AM, Dale P, Murray JL, Grdina DJ. The inhibition of radiation-induced Mutagenesis by the combined effects of selenium and the aminothiol WR-1065. Mutation Research. 1996; 356: 147-154. (Pubitemid 26302884)
25. Doerr W. Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol. 2006; 182: 693-695.
26. Gehrisch A, Doerr W. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol. 2007; 183: 36-42. (Pubitemid 46144103)
27. Margulies BS, Damron TA, Allen MJ. The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, Ewing's sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro. J Orthop Res. 2008; 26: 1512-1519.
28. Mutlu-Tuerkoglu UE, Erbil Y, Oztezcan S, Olgac V, Toker G, Uysal M. The effect of selenium and/ or vitamin E treatments on radiation-induced intestinal injury in rats. Life Sciences. 2000; 66: 1905-1913. (Pubitemid 30213164)
29. Patchen ML, MacVittie TJ, Weiss JF. Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys. 1990; 18: 1069-1075. (Pubitemid 20182339)
30. Rodemann HP, Hehr T, Bamberg M. Relevance of the radioprotective effect of sodium selenite. Med Klin (Munich). 1999; 94 (Suppl 3): 39-41.
31. Schleicher UM, Lopez Cotarelo C, Andreopoulos D, Handt S, Ammon J. Radioprotection of human endothelial cells by sodium selenite. Med Klin (Munich). 1999; 94 (Suppl 3): 35-38. (Pubitemid 29528789)
32. Schueller P, Puettmann S, Muecke R, Senner V, Schaefer U, Kisters K, Micke O. From the radiolysis of water to the role of trace elements in radiobiology and clinical radiation therapy: following a logical chain. Trace Elem Electrolytes. 2001; 18: 34-36, 186-192. (Pubitemid 32971115)
33. Weiss JF, Hoover RL, Kumar KS. Selenium enhances the radioprotective effect and reduces the lethal toxicity of WR-2721. Free Radic Res Commun. 1987; 3: 33-38.
34. Weiss JF, Landauer MR. History and development of radiation-protective agents. Int J Radiat Biol. 2009; 85: 539-573.
35. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci. 2000; 57: 1825-1835. (Pubitemid 32102578)
36. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN. Characterization of mammalian selenoproteomes. Science. 2003 ; 300: 1439-1443. (Pubitemid 36638165)
37. Epp O, Ladenstein R, Wendel A. The refined structure of the selenoenzyme glutathione peroxidase at 0.2 nm resolution. Eur J Biochem. 1983; 133: 51-69.
38. Conrad M, Schweizer U. Unveiling the molecular mechanisms behind selenium-related diseases through knockout mouse studies. Antioxid Redox Signal. 2010; 12: 851-865.
39. Zhung W, Yan T, Lim R, Oberley LW. Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells. Free Radic Biol Med. 1999; 27: 1334-1345. (Pubitemid 30001496)
40. Hehr T, Bamberg M, Rodemann HP. Präklinische und klinische Relevanz der radiopro-tektiven Wirkung von Natriumselenit. InFoOnkologie. 1999; 2 (Suppl 2): 25-29.
41. Davis RL, Spallholz JE. Inhibition of selenitecatalyzed superoxide generation and formation of elemental selenium (Se0) by copper, zinc, and aurintricarboxylic acid (ATA). Biochem Pharmacol. 1996; 51: 1015-1020. (Pubitemid 26104623)
42. Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med. 1994; 17: 45-64. (Pubitemid 24212711)
43. Lanfear J, Fleming J, Wu L, Webster G, Harrison PR. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemoprotective effects of selenium? Carcinogenesis. 1994; 15: 1387-1392.
44. Lu JX, Kaeck M, Jiang C, Wilson AC, Thompson HJ. Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. Biochem Pharmacol. 1994; 47: 1531-1535. (Pubitemid 24167263)
45. Shin SH, Yoon MJ, Kim M, Kim JI, Lee SJ, Lee YS, Bae S. Enhanced lung cancer cell killing by the combination of selenium and ionizing radiation. Oncology Reports. 2007; 17: 209-216.
46. Stewart MS, Spallholz JE, Neldner KH, Pence BC. Selenium compounds have disparate abilities to impose oxidative stress and include apoptosis. Free Radic Biol Med. 1999; 26: 42-48. (Pubitemid 29001492)
47. Frisk P, Saetre A, Couce B, Stenerlow B, Carlsson J, Lindh U. Effects of Pb2+, Ni2+, Hg2+ and Se4+ on cultured cells. Analysis of uptake, toxicity and influence on radiosensitivity. BiolMetals. 1997; 10: 263-270.
48. Schueller P, Puettmann S, Micke O, Senner V, Schaefer U, Willich N. Selenium influences the radiation sensitivity of C6 rat glioma cells. Anticancer Res. 2004; 24: 2913-2917. (Pubitemid 39407166)
49. Schueller P, Puettmann S, Micke O, Senner V, Schaefer U, Willich N. Selenium - a novel radiosensitizer? Trace Elem Electrolytes. 2005; 22: 201-206.
50. Gudkov AV. Converting p53 from a killer to a healer. Nature Medicine. 2002; 8: 1196-1198.
51. Fischer JL, Mihelc EM, Pollok KE, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther. 2007; 6: 355-361.
52. Beck MA, Nelson HK, Shi Q, Van Dael P, Schiffrin EJ, Blum S, Barclay D, Levander OA. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J. 2001; 15: 1481-1483.
53. Vunta H, Davis F, Palempalli UD, Bhat D, Arner RJ, Thompson JT, Peterson DG, Reddy CC, Prabhu KS. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J Biol Chem. 2007; 282: 17964-17973. (Pubitemid 47100228)
54. Buentzel J, Muecke R, Micke O. Mineral status and enzymatic antioxidative capacities during radiochemotherapy in patients with advanced head and neck cancer. Trace Elem Electrolytes. 2000; 18: 98.
55. Buentzel J, Micke O, Muecke R, Schoenekaes KG, Schaefer U, Kisters K, Bruns F. Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer - redox status data.Trace Elem Electrolytes. 2005; 22: 211-215.
56. Asfour IA, Shazly SE, Fayek MH, Hegab HM, Raouf S, Moussa MA. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients. Biol Trace Elem Res. 2006; 110: 19-32. (Pubitemid 43780413)
57. Asfour IA, Fayek MH, Raouf S, Soliman M, Hegab HM, El-Desoky H, Saleh R, Moussa MA. The impact of high-dose sodium selenite therapy on Bcl- 2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Biol Trace Elem Res. 2007; 120: 1-10. (Pubitemid 350085226)
58. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel- Sattar MA, Moustafa NN, Hegab HM, Fathey OM. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma. Biol Trace Elem Res. 2009; 127: 200-210.
59. Buentzel J, Micke O, Glatzel M, Schaefer U, Riesenbeck D, Kisters K, Bruns F, Schoenekaes KG, Dawczynski H, Muecke R. Selenium substitution during radiotherapy in head and neck cancer. Trace Elem Electrolytes. 2010; 27: 235-239.
60. Funke AM. Potential of selenium in gynecological oncology. Med Klin. 1999; 94: 42-44.
61. Fraunholz I, Jueling-Pohlit L, Boettcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors. Trace Elem Electrolytes. 2001; 18: 98-99.
62. Hehr T, Hoffmann W, Bamberg M. Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma. Med Klin. 1997; 92 (Suppl 3): 48-49. (Pubitemid 27404621)
63. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, Luo L, Xu PM, Zhao YN, Zhao YB, Cheng G. The protective role of selenium on the toxicity of cisplatinum-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997; 56: 331-341. (Pubitemid 27255781)
64. Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol. 2004; 93: 320-327. (Pubitemid 38507596)
65. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo- controlled study. Eur J Cancer. 2004; 40: 1713-1723. (Pubitemid 38902907)
66. Last KW, Cornelius V, Delves T, Sieniawska CH, Fitzgibbon J, Norton A, Amess J, Wilson A, Rohatiner A, Lister AT. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 2335-2341. (Pubitemid 46621872)
67. Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, Lister TA, Joel S. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol. 2006; 17: 773-779.
68. Muecke R, Schomburg L, Glatzel M, Bernd-Skorka R, Baaske D, Reichl B, Buentzel J, Kundt G, Prott FJ, De Vries A, Stoll G, Kisters K, Bruns F, Schaefer U, Willich N, Micke O. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys. 2010; 70: 828-835.
69. Buentzel J, Riesenbeck D, Glatzel M, Berndt-Skorka R, Riedel T, Muecke R, Kisters K, Schoenekaes KG, Schaefer U, Bruns F, Micke O. Limited effects of selenium substitution in the prevention of radiation- associated toxicities. Results of a randomized study in head neck cancer patients. Anticancer Research. 2010; 30: 1829-1832.
70. Bruns F, Buentzel J, Muecke R, Schoenekaes K, Kisters K, Micke O. Selenium in the treatment of head and neck lymphedema. Med Princ Pract. 2004; 13: 185-190. (Pubitemid 38812932)
71. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res. 1998; 18: 2227-2230. (Pubitemid 28386495)
72. Micke O, Bruns F, Muecke R, Schaefer U, Glatzel M, DeVries AF, Schoenekaes K, Kisters K, Büntzel J. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys. 2003; 56: 40-49. (Pubitemid 36403675)
73. Brenke R, Siems W, Grune T. Measures for therapy optimization in chronic lymphedema. Z Lymphol. 1997; 21: 1-29.
74. Schrauzer GN. Selenium in the therapy of chronic lymphedema - mechanistic perspectives and practical applications. Z Lymphol. 1997; 21: 16-19.
75. Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ. Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci. 2001; 100: 543-550. (Pubitemid 32434120)
76. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 147: 217-223. (Pubitemid 351664577)
77. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008; 168: 404-410. (Pubitemid 351347132)
78. Micke O, Schomburg L, Buentzel J, Kisters K, Muecke R. Selenium in oncology - an update. Trace Elem Electrolytes. 2010; 27: 250-257.
79. Muecke R, Schomburg L, Buentzel J, Gröber U, Holzhauer P, Micke O. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe. 2010; 16: 181-186.
80. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O. Blood selenium status in tumor patients - Omnia sunt venena, nihil est sine veneno. Sola dosis facit venenum. Trace Elem Electrolytes. 2010; 27: 181-184.
81. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O. Selenium or no selenium - that is the question in tumor patients: a new controversy. Integr Cancer Ther. 2010; 9: 136-141.
82. Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006; 3: CD005037.
83. Buentzel J, Büntzel H, Micke O, Kisters K, Bruns F, Glatzel M, Muecke R, Schoenekaes KG, Schaefer U. Complementary and alternative medicine (CAM) use in terminally ill patients. Trace Elem Electrolytes. 2011; 28: 49-51.
84. Micke O, Bruns F, Glatzel M, Schoenekaes KG, Micke P, Muecke R, Buentzel J. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine. 2009; 1: 22-30.
85. Muecke R, Micke O, Schoenekaes KG, Buentzel J. Is a supplementation of selenium advisable during radiotherapy and radiochemotherapy of patients with malignant diseases? Trace Elem Electrolytes. 2000b; 17: 194-195.